CCN1: A sticky issue in myeloma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this issue of Blood, Johnson et al report that patients with high CCN1 levels in their marrow who were treated in the Total Therapy 3 trial have a prolonged overall survival and better progression-free survival than patients with lower levels of CCN1.

Original languageEnglish
Pages (from-to)2006-2008
Number of pages3
JournalBlood
Volume124
Issue number13
StatePublished - Sep 25 2014

Fingerprint

Blood
Disease-Free Survival
Bone Marrow
Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

CCN1 : A sticky issue in myeloma. / Roodman, G. David.

In: Blood, Vol. 124, No. 13, 25.09.2014, p. 2006-2008.

Research output: Contribution to journalArticle

Roodman, GD 2014, 'CCN1: A sticky issue in myeloma', Blood, vol. 124, no. 13, pp. 2006-2008.
Roodman GD. CCN1: A sticky issue in myeloma. Blood. 2014 Sep 25;124(13):2006-2008.
Roodman, G. David. / CCN1 : A sticky issue in myeloma. In: Blood. 2014 ; Vol. 124, No. 13. pp. 2006-2008.
@article{ee6a7d9693464ce89a992e00603f4300,
title = "CCN1: A sticky issue in myeloma",
abstract = "In this issue of Blood, Johnson et al report that patients with high CCN1 levels in their marrow who were treated in the Total Therapy 3 trial have a prolonged overall survival and better progression-free survival than patients with lower levels of CCN1.",
author = "Roodman, {G. David}",
year = "2014",
month = "9",
day = "25",
language = "English",
volume = "124",
pages = "2006--2008",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - CCN1

T2 - A sticky issue in myeloma

AU - Roodman, G. David

PY - 2014/9/25

Y1 - 2014/9/25

N2 - In this issue of Blood, Johnson et al report that patients with high CCN1 levels in their marrow who were treated in the Total Therapy 3 trial have a prolonged overall survival and better progression-free survival than patients with lower levels of CCN1.

AB - In this issue of Blood, Johnson et al report that patients with high CCN1 levels in their marrow who were treated in the Total Therapy 3 trial have a prolonged overall survival and better progression-free survival than patients with lower levels of CCN1.

UR - http://www.scopus.com/inward/record.url?scp=84907266508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907266508&partnerID=8YFLogxK

M3 - Article

C2 - 25258135

AN - SCOPUS:84907266508

VL - 124

SP - 2006

EP - 2008

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -